JonesTrading analyst Soumit Roy has reiterated their bullish stance on TARA stock, giving a Buy rating on September 17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors that highlight the potential of Protara Therapeutics’ TARA-002 in the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). Despite the competitive landscape, the mechanism of action of TARA-002, which is similar to BCG but with superior manufacturing, makes it a compelling option, especially given the current BCG shortage affecting large hospital systems. The cautious optimism from urology experts and the upcoming data updates over the next six months are expected to further clarify the drug’s therapeutic benefits.
In addition to the bladder cancer treatment, Protara Therapeutics is advancing other promising programs. The company is anticipating key readouts from their TARA-002 program in lymphatic malformations and their IV Choline asset for patients on parenteral nutrition. These developments are expected in late 2025 and mid-2026, respectively, which could further enhance the company’s value proposition. The interim readout from the Phase 2 ADVANCED-2 study with TARA-002 in NMIBC, expected in early 2026, will provide additional insights into the drug’s efficacy, reinforcing the Buy rating.
In another report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $23.00 price target.